Abstract 152P
Background
The detection of copy number alterations (CNAs) is an informative molecular layer in the diagnosis, prognosis, and treatment of lung adenocarcinoma. Traditional tissue biopsies are invasive and often impractical. This study investigates the use of nanopore sequencing on circulating cell-free DNA (cfDNA) as a non-invasive, PCR-free method to detect CNAs in lung adenocarcinoma patients.
Methods
Native cfDNA samples from lung adenocarcinoma patients were analysed using low coverage nanopore sequencing (∼ 1- 3 X). Bioinformatics analysis identified CNAs, which were compared to known CNA patterns in tissue samples. Additionally, tumor fractions were estimated to correlate with tumor stage and aggressiveness.
Results
Nanopore sequencing of cfDNA revealed clinically significant and informative CNAs, including amplifications of 1q (MDM4), chromosome 7 (EGFR) as well as deletion of 8p. These alterations closely mirrored the classic CNA patterns observed in lung adenocarcinoma tissue samples, especially in cfDNA samples derived from patients with progressive cancers (i.e. stage 3-4). The analysis also provided tumor fraction estimates, which correlated with tumor stage and aggressiveness.
Conclusions
This study demonstrates that nanopore sequencing of cfDNA can accurately detect CNAs and estimate tumor fractions, offering a non-invasive alternative to tissue biopsies. This approach holds significant potential for real-time cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. Estimating tumor fractions is also useful for predicting cancer progression and determining future sequencing coverage and planning.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Renovaro Cube.
Disclosure
K. Roohollahi, E. Post, D. Makarawung, F. van Asch: Financial Interests, Institutional, Stocks/Shares: Renovaro Cube. D. Vessies, J. van den Berg: Financial Interests, Personal, Stocks/Shares: Renovaro Cube.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract